* Pacific Biosciences of California Inc PACB.OQ reported a
quarterly adjusted loss of 31 cents per share for the quarter
ended in December, higher than the same quarter last year, when
the company reported EPS of -37 cents. The mean expectation of
fifteen analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -35 cents
to -24 cents per share.
* Revenue rose 113.3% to $58.36 million from a year ago;
analysts
expected $57.49 million.
* Pacific Biosciences of California Inc's reported EPS for
the
quarter was a loss of 31 cents.
* The company reported a quarterly loss of $82.02 million.
* Pacific Biosciences of California Inc shares had fallen
by 33.7%
this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $12.00
This summary was machine generated from LSEG data February 15 at
11:29 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.29 -0.31 Missed
Sep. 30 2023 -0.33 -0.26 Beat
Jun. 30 2023 -0.32 -0.28 Beat
Mar. 31 2023 -0.33 -0.36 Missed